- MOQ 10 Pack
- Brand NameMounjaro
- TasteNormal
- GradeA
- FormLiquid
- Packaging Size20-30cap
- CertificationFDA Certified, FSSAI Certified, ISO 9001:2008
- Purity100%
- Packaging TypeBottle
- Dosage Forminjections
- ColorWhite
- ConditionNew
- ApplicationPersonal
- TypeWeight Loss Supplements
- Shelf Life2 Year
- FeatureGood Purity
- Country of OriginIndia
- Other NamesSemaglutide injections
Mounjaro (tirzepatide) is a new drug indicated for treating type 2 diabetes in adult patients. Mounjaro, developed by Eli Lilly to improve glycemic control, works best, as with all antidiabetic medications, with diet and exercise. Mounjaro administration provided proper glycemic control in almost 90% of patients whose glycated hemoglobin level (HbA1c) dropped below 7.0% as the American Diabetes Association (ADA) recommended target for type 2 diabetes. At the same time, more than half of the patients who received the maximum dose of Mounjaro and strictly followed the therapeutic regimen had their HbA1c level lowered to less than 5.7%, a level fair for individuals without diabetes. Additionally, Mounjaro was successful in getting patients off the excess weight and reducing the risk of cardiovascular complications quite well.